FAH and tyrosinemia type I: Thus, the chimeric mouse model fumarylacetoacetate hydrolase (Fah−/−), Rag2−/−, Ilr2g−/− NOD-(FRGN) mouse39,40 has been used to create and screen for novel, engineered rAAV capsids highly efficient in transducing the liver41–43, such as AAVLK0341.The combination of immune deficiency and tyrosinemia type I enables xenotransplantation and repopulation of the liver with a wide variety of species.